The string of companies declaring Q2 results continues, and Aurobindo Pharma becomes the latest to reveal its September quarter performance for FY27. Aurobindo Pharma’s net profit rose 32.8% year-on-year to Rs 1,126 crore, compared with Rs 848 crore in the corresponding quarter last year. The pharmaceutical company’s revenue from operations increased 23.9% to Rs 10,263 crore in Q2 FY27, against Rs 8,286 crore reported in the year-ago period.
On the operational front, Aurobindo Pharma posted a 24.1% jump in EBITDA to Rs 2,155 crore, compared with Rs 1,678 crore in the corresponding quarter of the previous fiscal.
The company’s EBITDA margin also witnessed a considerable improvement as it rose to 21% in the September quarter, compared with 20% in Q2 FY26, indicating an expansion of 100 basis points.
Besides the Q2 results, the company declared an interim dividend of Rs 7 per share for its shareholders.
Aurobindo Pharma Q2 Results: Key highlights (YoY)
- Consolidated net profit: Rs 1,126 crore vs Rs 848 crore, up 32.8%.
- Revenue: Rs 10,263 crore vs Rs 8,286 crore, up 23.9%.
- EBITDA: Rs 2,155 crore vs Rs 1,678 crore, up 24.1%.
- EBITDA margin: 21% vs 20%, up 100 basis points.
- Interim dividend: Rs 7 per share.